FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080347660> ?p ?o ?g. }

• W2080347660 endingPage "260" @default.
• W2080347660 startingPage "250" @default.
• W2080347660 abstract "BACKGROUND Experimental evidence suggests a role for the β2-adrenergic receptor pathway in prostate cancer (PCa). We have investigated the association of β-blocker use with PCa incidence and survival in a Norwegian cohort. METHODS Data from the Oslo II study in 2000 (n = 6515) were linked with information from the Cancer Registry of Norway and Statistics Norway. PCa risk and overall- and PCa-specific mortality were analyzed using uni- and multi-variable Cox- and competing risk regression models. RESULTS At baseline, 776 men (11.9%) reported using a β-blocker. 212 men (3.3%) were diagnosed with PCa before the survey, leaving 6,303 eligible for incidence analysis. During a median follow-up of 122 months, 448 (7.1%) men were diagnosed with PCa. β-blocker use was not associated with PCa risk [hazard ratio (HR): 1.05, 95% CI: 0.79–1.40]. For all patients (n = 655; including med diagnosed before the survey), β-blocker use was not associated with PCa-specific mortality (HR: 0.55, 95% CI 0.24–1.26, P = 0.16). However, in the subgroup of men planned to receive androgen deprivation therapy (ADT), as reported to the Cancer Registry (n = 263), β-blocker use was associated with reduced PCa-specific mortality (HR: 0.14, 95% CI 0.02–0.85, P = 0.032). No effect on overall mortality was seen (HR, all patients: 0.88, 95% CI 0.56–1.38, P = 0.57). β-blocker use did not appear to affect PSA level, Gleason score, or T-stage at diagnosis; however, these variables were missing for many cases. CONCLUSIONS Our findings demonstrate a possible benefit of β-blocker use for men treated with ADT, suggesting the need for investigation in larger cohorts. Prostate 73: 250–260, 2013. © 2012 Wiley Periodicals, Inc." @default.
• W2080347660 created "2016-06-24" @default.
• W2080347660 creator A5012835670 @default.
• W2080347660 creator A5026839013 @default.
• W2080347660 creator A5042002968 @default.
• W2080347660 creator A5061978274 @default.
• W2080347660 creator A5062805582 @default.
• W2080347660 date "2012-07-20" @default.
• W2080347660 modified "2023-09-29" @default.
• W2080347660 title "Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy" @default.
• W2080347660 cites W1609833541 @default.
• W2080347660 cites W1970127699 @default.
• W2080347660 cites W1970473792 @default.
• W2080347660 cites W1972421517 @default.
• W2080347660 cites W1980670486 @default.
• W2080347660 cites W1983145936 @default.
• W2080347660 cites W1997930286 @default.
• W2080347660 cites W2000961343 @default.
• W2080347660 cites W2012863869 @default.
• W2080347660 cites W2013102352 @default.
• W2080347660 cites W2019300436 @default.
• W2080347660 cites W2020961525 @default.
• W2080347660 cites W2036776292 @default.
• W2080347660 cites W2038118918 @default.
• W2080347660 cites W2041230761 @default.
• W2080347660 cites W2052690305 @default.
• W2080347660 cites W2068398299 @default.
• W2080347660 cites W2070678426 @default.
• W2080347660 cites W2074555738 @default.
• W2080347660 cites W2088138591 @default.
• W2080347660 cites W2089559603 @default.
• W2080347660 cites W2090913755 @default.
• W2080347660 cites W2102893063 @default.
• W2080347660 cites W2113603797 @default.
• W2080347660 cites W2126071318 @default.
• W2080347660 cites W2141382054 @default.
• W2080347660 cites W2170674837 @default.
• W2080347660 cites W2171415105 @default.
• W2080347660 cites W4293409513 @default.
• W2080347660 cites W4322700960 @default.
• W2080347660 doi "https://doi.org/10.1002/pros.22564" @default.
• W2080347660 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22821802" @default.
• W2080347660 hasPublicationYear "2012" @default.
• W2080347660 type Work @default.
• W2080347660 sameAs 2080347660 @default.
• W2080347660 citedByCount "120" @default.
• W2080347660 countsByYear W20803476602012 @default.
• W2080347660 countsByYear W20803476602013 @default.
• W2080347660 countsByYear W20803476602014 @default.
• W2080347660 countsByYear W20803476602015 @default.
• W2080347660 countsByYear W20803476602016 @default.
• W2080347660 countsByYear W20803476602017 @default.
• W2080347660 countsByYear W20803476602018 @default.
• W2080347660 countsByYear W20803476602019 @default.
• W2080347660 countsByYear W20803476602020 @default.
• W2080347660 countsByYear W20803476602021 @default.
• W2080347660 countsByYear W20803476602022 @default.
• W2080347660 countsByYear W20803476602023 @default.
• W2080347660 crossrefType "journal-article" @default.
• W2080347660 hasAuthorship W2080347660A5012835670 @default.
• W2080347660 hasAuthorship W2080347660A5026839013 @default.
• W2080347660 hasAuthorship W2080347660A5042002968 @default.
• W2080347660 hasAuthorship W2080347660A5061978274 @default.
• W2080347660 hasAuthorship W2080347660A5062805582 @default.
• W2080347660 hasBestOaLocation W20803476602 @default.
• W2080347660 hasConcept C120665830 @default.
• W2080347660 hasConcept C121332964 @default.
• W2080347660 hasConcept C121608353 @default.
• W2080347660 hasConcept C126322002 @default.
• W2080347660 hasConcept C126894567 @default.
• W2080347660 hasConcept C143998085 @default.
• W2080347660 hasConcept C170493617 @default.
• W2080347660 hasConcept C207103383 @default.
• W2080347660 hasConcept C2775864247 @default.
• W2080347660 hasConcept C2776235491 @default.
• W2080347660 hasConcept C2777899217 @default.
• W2080347660 hasConcept C2778527826 @default.
• W2080347660 hasConcept C2780192828 @default.
• W2080347660 hasConcept C2910298800 @default.
• W2080347660 hasConcept C29456083 @default.
• W2080347660 hasConcept C37000724 @default.
• W2080347660 hasConcept C44249647 @default.
• W2080347660 hasConcept C50382708 @default.
• W2080347660 hasConcept C61511704 @default.
• W2080347660 hasConcept C71924100 @default.
• W2080347660 hasConcept C72563966 @default.
• W2080347660 hasConceptScore W2080347660C120665830 @default.
• W2080347660 hasConceptScore W2080347660C121332964 @default.
• W2080347660 hasConceptScore W2080347660C121608353 @default.
• W2080347660 hasConceptScore W2080347660C126322002 @default.
• W2080347660 hasConceptScore W2080347660C126894567 @default.
• W2080347660 hasConceptScore W2080347660C143998085 @default.
• W2080347660 hasConceptScore W2080347660C170493617 @default.
• W2080347660 hasConceptScore W2080347660C207103383 @default.
• W2080347660 hasConceptScore W2080347660C2775864247 @default.
• W2080347660 hasConceptScore W2080347660C2776235491 @default.
• W2080347660 hasConceptScore W2080347660C2777899217 @default.
• W2080347660 hasConceptScore W2080347660C2778527826 @default.

• next